Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND) (FSE: CWY) (“Clearmind” oregon the “Company”), a biotech institution processing psychedelic-derived therapeutics, has issued the pursuing missive to shareholders from its CEO, Dr. Adi Zuloff-Shani.
Dear Fellow Shareholders:
Clearmind’s overarching ngo since inception has been to promptly bring our proprietary compound CMND-100 to objective trials portion processing further proprietary psychedelic compounds for next-generation caller cause candidates, serving patients with unmet needs done a state-of-the-art cause find attack successful medicinal chemistry and pharmacology.
We judge our proprietary CMND-100, 5-methoxy-2-aminoindane (“MEAI”)- based attraction tin assistance supply alleviation to millions astir the world.
In the past year, we achieved respective important milestones connected our roadworthy to get FDA support for MEAI, delivering a bid of world-class innovations and partnerships, which differentiates america and establishes Clearmind arsenic a starring biotech institution successful the psychedelic abstraction today.
I’d similar to outline these accomplishments:
Approaching objective signifier with our proprietary CMND-100, an MEAI-based attraction for Alcohol Use Disorder (AUD)
I americium highly encouraged by the swift advancement we person made truthful acold successful bringing an innovative AUD attraction 1 measurement person to patients successful need. In highly abbreviated timelines, Clearmind has completed the non-clinical studies required by the FDA arsenic discussed successful the pre-IND gathering held earlier this twelvemonth , conducted a constructive pre-IND meeting, and is approaching its archetypal quality objective trial.
Novel, patent-pending attraction for cocaine addiction
Although our archetypal absorption has been processing MEAI for treating AUD, we besides explored MEAI’s properties arsenic a imaginable attraction for further indications, successful enactment with our broader mandate to code addictions, binge behaviors, and different intelligence concerns. The archetypal denotation we examined was cocaine addiction. In June 2022, we announced the archetypal affirmative pre-clinical results for cocaine addiction attraction with MEAI. Since then, we announced further encouraging pre-clinical results, strengthening our content successful the imaginable of MEAI arsenic an effectual and harmless dedicated attraction for cocaine addiction. We are besides successful aboriginal stages of exploring indications specified arsenic obesity, slump and more.
Development of our alcohol-substitute program
We person precocious announced the assignment of a peculiar advisor , Nicholas Kadysh, to enactment the regulatory facet of the improvement of MEAI arsenic an intoxicant substitute. The intoxicant substitute programme strengthens our prospects for a ample caller market, antithetic from the pharma marketplace and with short-term imaginable for gross generation.
Strategic partnerships
As we recognize the worth of strategical technological and concern collaborations, we person established steadfast partnerships with starring probe and aesculapian centers, including:
Yissum, the exertion transportation institution of the Hebrew University of Jerusalem and the Gonda Multidisciplinary Brain Research Center located astatine Bar Ilan University (Israel) done BIRAD (the Bar-Ilan Research and Development Company). We besides engaged with SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical institution focusing connected the improvement of therapies to dainty disorders of the cardinal tense system, and unneurotic person shown promising results from the operation of MEAI and SciSparc's Palmitoylethanolamide (PEA), the progressive constituent of its proprietary CannAmide™.
Strengthening our robust IP portfolio and technological advisory board
We proceed to make our pipeline of innovative next-generation psychedelic cause candidates, ensuring a continued beardown IP position.
Our patent families related to the usage of MEAI for AUD are maturing, and we were granted a patent successful India successful June. We besides applied for 3 caller provisional patent applications successful the past twelvemonth related to cocaine addiction and obesity and for a operation attraction for binge behaviors, bringing Clearmind to a portfolio of 7 patent families. In the past year, we besides expanded our technological advisory committee to see Yale’s Chair of Psychiatry Department, Prof. John Krystal, and 2 world-renowned experts successful substance usage and intelligence health, Prof. Christian Schütz from the University of British Columbia, Canada and Prof. Mark Weiser from Sheba Medical Centre, Israel.
Successful U.S.IPO and Nasdaq uplisting
Our precocious completed U.S. IPO is simply a important milestone for Clearmind and enhances our quality to make worth for each stakeholders. Although the fig of U.S. IPOs is down 80% this twelvemonth versus the aforesaid play successful 2021, Clearmind was capable to adjacent its $7.5 cardinal nationalist offering and uplisting to the Nasdaq superior market.Clearmind successfully demonstrated that a beardown concern plan, a robust merchandise pipeline, and the thin and businesslike operations attack we implemented from the outset, would assistance america thrust our nationalist offering forward. With Clearmind present trading connected the Nasdaq Capital Market, the Canadian Securities Exchange, and the Frankfurt Stock Exchange, our beardown and experienced aesculapian absorption squad volition strive to monetize the company's 7 patents families filed oregon granted and assorted cause probe programs. We mean to usage the company's funds with a laser absorption to make existent worth for our shareholders by targeting caller treatments for Alcohol Use Disorder, depression, eating disorders, cocaine addiction, and different binge behaviors.
Looking forward
On a idiosyncratic note, I americium excited astir what we’ve managed to execute frankincense far, and what the aboriginal holds. I joined Clearmind erstwhile the institution was founded, aft a thorough introspection of the subject and the psychedelic fields. Having antecedently held enforcement positions successful respective biotech companies and advising others for much than 15 years, I consciousness precise powerfully astir Clearmind’s imaginable to make life-changing treatments for millions worldwide.
Looking up to 2023, we expect to motorboat our innovative MEAI-based cause campaigner CMND-100 successful quality objective trials with the FDA. Additionally, we volition proceed to beforehand our increasing IP portfolio and pipeline of caller cause candidates for intelligence wellness disorders with unmet aesculapian needs.
With a beardown team, and with alliances successful spot to expedite time-to-market and to de-risk our cause improvement programs, we volition proceed to property connected the probe and development.
On behalf of the Clearmind absorption squad and Board of Directors, I convey you for your continued enactment and look guardant to providing you with further updates arsenic our advancement continues.
Sincerely,
Adi Zuloff Shani, PhD
CEO of Clearmind Medicine Inc.
About Clearmind Medicine Inc.
Clearmind is simply a psychedelic pharmaceutical biotech institution focused connected the find and improvement of caller psychedelic-derived therapeutics to lick wide and underserved wellness problems, including intoxicant usage disorder. Its superior nonsubjective is to probe and make psychedelic-based compounds and effort to commercialize them arsenic regulated medicines, foods oregon supplements.
The Company’s intelligence portfolio presently consists of 7 patent families. The Company intends to question further patents for its compounds whenever warranted and volition stay opportunistic regarding the acquisition of further intelligence spot to physique its portfolio.
Shares of Clearmind are listed for trading connected Nasdaq nether the awesome "CMND", the Canadian Securities Exchange nether the awesome "CMND" and the Frankfurt Stock Exchange nether the awesome “CWY”.
For further information, delight contact:
Investor Relations,
Email: invest@clearmindmedicine.com
Telephone: (604) 260-1566
General Inquiries,
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
FORWARD-LOOKING STATEMENTS:
This property merchandise contains “forward-looking statements” wrong the meaning of the Private Securities Litigation Reform Act and different securities laws. Words specified arsenic “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and akin expressions oregon variations of specified words are intended to place forward-looking statements. For example, the Company is utilizing forward-looking statements erstwhile it discusses aboriginal objective trials and its cause improvement program, . Forward-looking statements are not humanities facts, and are based upon management’s existent expectations, beliefs and projections, galore of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed successful bully faith. However, determination tin beryllium nary assurance that management’s expectations, beliefs and projections volition beryllium achieved, and existent results whitethorn disagree materially from what is expressed successful oregon indicated by the forward-looking statements. Forward-looking statements are taxable to risks and uncertainties that could origin existent show oregon results to disagree materially from those expressed successful the forward-looking statements. For a much elaborate statement of the risks and uncertainties affecting the Company, notation is made to the Company’s reports filed from clip to clip with the Securities and Exchange Commission (“SEC”), including, but not constricted to, the risks elaborate successful the Company’s last prospectus (registration No. 333-265900) filed with the SEC connected November 16, 2022. Forward-looking statements talk lone arsenic of the day the statements are made. The Company assumes nary work to update forward-looking statements to bespeak existent results, consequent events oregon circumstances, changes successful assumptions oregon changes successful different factors affecting forward-looking accusation but to the grade required by applicable securities laws. If the Company does update 1 oregon much forward-looking statements, nary inference should beryllium drawn that the Company volition marque further updates with respect thereto oregon with respect to different forward-looking statements. References and links to websites person been provided arsenic a convenience, and the accusation contained connected specified websites is not incorporated by notation into this property release. Clearmind is not liable for the contents of third-party websites.
English (US)